Loading…
Bicara Therapeutics Inc. is projected to rise to $34.07 by 2027, a +30% move from its current price of $26.27. BCAX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $25.67 | $26.28 | $26.90 | +0.04% |
| Aug 2 | $25.44 | $26.29 | $27.17 | +0.07% |
| Aug 3 | $25.26 | $26.30 | $27.38 | +0.11% |
| Aug 4 | $25.11 | $26.31 | $27.56 | +0.14% |
| Aug 5 | $24.98 | $26.32 | $27.72 | +0.18% |
| Aug 6 | $24.87 | $26.33 | $27.87 | +0.22% |
| Aug 7 | $24.76 | $26.34 | $28.01 | +0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $24.76 | $26.34 | $28.01 | +0.25% |
| Week 2 | $24.20 | $26.40 | $28.81 | +0.51% |
| Week 3 | $23.79 | $26.47 | $29.45 | +0.76% |
| Week 4 | $23.46 | $26.54 | $30.02 | +1.02% |
| Week 5 | $23.18 | $26.60 | $30.53 | +1.27% |
| Week 6 | $22.93 | $26.67 | $31.02 | +1.53% |
| Week 7 | $22.72 | $26.74 | $31.47 | +1.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc. (BCAX) trades at $27.15 per share and has a market capitalization of $1.78B. It ranks 2007 in market capitalization among publicly traded entities.
The longer-run price outlook in the forecast shows a path of growth, with the 2026 average price at $27.15 and a neutral sentiment. The forecast projects progressively higher averages in later years, indicating bullish potential with substantial upside by 2030 and beyond.
From 2027 onward, the forecast assigns bullish sentiment and rising average prices, with 2030 at an average of $66.57 and 2040 at $207.09, culminating in a 2050 average of $476.16. The implied ROIs climb from the mid-teens in the near term to very large gains by the end of the horizon.
A major floor 30.9% below — a decisive break under it would weaken the trend.
The nearest floor, 12.8% below — buyers have tended to step in here.
The nearest ceiling, 15.7% above — a clean break opens room to run.
A major ceiling 29.5% above — clearing it would confirm fresh momentum.
Key BCAX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCAX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $26.77 | Sell | $26.68 | Sell |
| MA 10 | $27.26 | Sell | $27.11 | Sell |
| MA 20 | $28.04 | Sell | $27.14 | Sell |
| MA 50 | $24.83 | Buy | $25.55 | Buy |
| MA 100 | $22.97 | Buy | $23.36 | Buy |
| MA 200 | $19.88 | Buy | $20.75 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.54 | Neutral |
| Stoch RSI (14) | 14.54 | Buy |
| CCI (20) | -141.72 | Sell |
| Williams %R (14) | -83.19 | Info |
| MACD (12,26,9) | -0.47 | Sell |
| ROC (12) | -6.51 | Sell |
| Bollinger %B (20,2) | 0.09 | Neutral |
| Stochastic %K (14) | 16.81 | Buy |
| TRIX (15) | 0.48 | Buy |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 33.27 | Neutral |
| Momentum (10) | -1.33 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 26.21 | Buy |
| ADX (14) | 20.76 | Sell |
| ATR (14) | 0.62 | Info |
The near-term technical picture shows bullish tilt on the 30-day horizon, with RSI(14) at 50 and a positive sentiment overall.
The 50-day simple moving average sits at $23.92, above the 200-day average of $19.49, suggesting a constructive intermediate-term path. Support is identified at $20.00 and resistance at $30.40, framing a trading range that tracks the 30-day activity from $23.21 to $31.76 and implies meaningful upside if the breakout occurs.
Volatility runs high, with annualized volatility at 50%, underscoring the potential for sizable swings around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.06 | $26.27 | $35.51 | 0% | Neutral | |
| $27.53 | $34.07 | $44.34 | +30% | Bullish | |
| $37.94 | $48.08 | $64.65 | +83% | Bullish | |
| $45.89 | $59.30 | $81.80 | +126% | Bullish | |
| $51.44 | $67.61 | $95.30 | +157% | Bullish | |
| $59.43 | $79.34 | $113.96 | +202% | Bullish | |
| $64.44 | $87.28 | $127.50 | +232% | Bullish | |
| $71.21 | $97.74 | $144.99 | +272% | Bullish | |
| $82.95 | $115.32 | $173.49 | +339% | Bullish | |
| $101.25 | $142.48 | $217.19 | +442% | Bullish | |
| $148.78 | $221.15 | $356.24 | +742% | Bullish | |
| $322.42 | $525.67 | $918.16 | +19.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $14.06 | $26.27 | $30.65 | +0.00% |
| August 2026 | $23.31 | $27.27 | $32.59 | +3.82% |
| September 2026 | $23.04 | $27.15 | $32.82 | -0.46% |
| October 2026 | $22.87 | $27.10 | $33.06 | -0.17% |
| November 2026 | $23.58 | $28.07 | $34.49 | +3.58% |
| December 2026 | $24.01 | $28.71 | $35.51 | +2.27% |
Click any year to see its month-by-month BCAX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BCAX price prediction for 2026 points to an average of $26.27 (low $14.06, high $35.51) — a potential gain of 0% on today's $26.27. A consolidation phase looks the most probable path here.
In 2027, BCAX is projected to trade between $27.53 and $44.34, averaging $34.07 — a potential gain of +30% from today's $26.27. That is up +30% on the projected 2026 average. Momentum favours further upside here.
Bicara Therapeutics Inc.'s 2028 outlook centres on $48.08, within a $37.94 to $64.65 range. That is up +41% on the projected 2027 average. That marks a +83% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, BCAX could reach as high as $81.80, with a base case around $59.30 and support toward $45.89 — roughly +126% from $26.27. Momentum favours further upside here.
Expect BCAX to range from $51.44 to $95.30 through 2030. The $67.61 average target implies a +157% move from current prices. That is up +14% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The BCAX price prediction for 2031 points to an average of $79.34 (low $59.43, high $113.96) — a potential gain of +202% on today's $26.27. Momentum favours further upside here.
In 2032, BCAX is projected to trade between $64.44 and $127.50, averaging $87.28 — a potential gain of +232% from today's $26.27. That is up +10% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Bicara Therapeutics Inc.'s 2033 outlook centres on $97.74, within a $71.21 to $144.99 range. That is up +12% on the projected 2032 average. That marks a +272% change versus current levels. Momentum favours further upside here.
By 2034, BCAX could reach as high as $173.49, with a base case around $115.32 and support toward $82.95 — roughly +339% from $26.27. Buyers look set to stay in control over this stretch.
Expect BCAX to range from $101.25 to $217.19 through 2035. The $142.48 average target implies a +442% move from current prices. That is up +24% on the projected 2034 average. Momentum favours further upside here.
The BCAX price prediction for 2040 points to an average of $221.15 (low $148.78, high $356.24) — a potential gain of +742% on today's $26.27. Buyers look set to stay in control over this stretch.
In 2050, BCAX is projected to trade between $322.42 and $918.16, averaging $525.67 — a potential gain of +19.0x from today's $26.27. That is up +138% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in BCAX today (≈ 38.066235 BCAX) could be worth
$20,010.31
+$19,010.31 (+1901%) by 2050 · US Dollar
Based on the average projected BCAX price of $525.67 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCAXwould be worth at today's price.
$1,000 invested in BCAX on Jul 30, 2025 (≈ 86.206894 BCAX) would be worth
$2,264.66
+$1,264.66 (+126.5%) today · 2.26× · US Dollar
Based on a BCAX entry price of $11.6 vs. today's $26.27.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $27.73 | $947.35 | -5.3% |
| 1 month ago | $29.69 | $884.81 | -11.5% |
| 3 months ago | $21.67 | $1,212.28 | +21.2% |
| 6 months ago | $16.8 | $1,563.69 | +56.4% |
| 1 year ago | $11.6 | $2,264.66 | +126.5% |
| All time (1.9y) ago | $23.41 | $1,122.17 | +12.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCAX forecast.
Our base-case forecast reaches $53.00 around 2029.
Implied market cap at $53.00: $3.48B
The multi-year forecast paints a bullish trajectory with rising averages and stronger upside potential over time.
By 2030, the average forecast price is $66.57 with a min of $50.48 and a max of $94.24, and an ROI of 145.2, indicating a solid long-run expansion in value with bullish sentiment.
By 2040, the average forecast price is $207.09 with a min of $138.45 and a max of $335.60, and an ROI of 662.8, reinforcing the expectation of substantial appreciation if the trajectory continues.
By 2050, the average forecast price is $476.16 with a min of $289.47 and a max of $837.57, and an ROI of 1653.8, with bullish sentiment continuing. These are estimates, not guarantees, and outcomes depend on market conditions, execution, and other factors.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $66.57, a min of $50.48, and a max of $94.24, with an ROI of 145.2 and bullish sentiment.
The forecast shows bullish sentiment from 2027 onward, with rising averages and ROIs (27.8 in 2027, 79.9 in 2028, 116.2 in 2029, 145.2 in 2030, 662.8 by 2040, and 1653.8 by 2050). These are estimates and not guarantees.
According to the forecast, the 2030 max is $94.24, which is below $100.
The current price is $27.15 and the market capitalization is $1.78B.
The 2040 forecast shows an average price of $207.09, a min of $138.45, and a max of $335.60, with an ROI of 662.8 and bullish sentiment.
Bicara Therapeutics Inc. Community Discussion
0Share your Bicara Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.